Lipella Pharmaceuticals Inc. (LIPO)
OTCMKTS · Delayed Price · Currency is USD
0.0800
-0.0022 (-2.68%)
Jun 10, 2026, 4:00 PM EST
Lipella Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2025
-
Proprietary liposomal technology enables targeted delivery for mucosal diseases, with LP-10 oral rinse showing strong safety and efficacy in phase two OLP trials. Addressing a significant unmet need, LP-10 targets a $750M peak sales opportunity, with next steps including a placebo-controlled trial and industry partnership.